These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 10695957

  • 1. HRT in the prevention and treatment of osteoporosis.
    Delmas PD.
    J Epidemiol Biostat; 1999; 4(3):155-60; discussion 160-3. PubMed ID: 10695957
    [Abstract] [Full Text] [Related]

  • 2. Prevention and treatment of osteoporosis with hormone replacement therapy.
    Christiansen C.
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():45-54. PubMed ID: 8499959
    [Abstract] [Full Text] [Related]

  • 3. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M, Vacca F.
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY.
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [Abstract] [Full Text] [Related]

  • 6. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C.
    Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
    [Abstract] [Full Text] [Related]

  • 7. [Evidence of hormone replacement therapy for osteoporosis].
    Tarakida A, Higuchi T, Mizunuma H.
    Clin Calcium; 2008 Oct; 18(10):1434-41. PubMed ID: 18830040
    [Abstract] [Full Text] [Related]

  • 8. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA, Going SB, Houtkooper LB, Flint-Wagner HG, Figueroa A, Metcalfe LL, Blew RM, Sharp SC, Lohman TG.
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [Abstract] [Full Text] [Related]

  • 9. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K.
    Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472
    [Abstract] [Full Text] [Related]

  • 10. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
    Col NF, Bowlby LA, McGarry K.
    Minerva Med; 2005 Oct 20; 96(5):331-42. PubMed ID: 16227948
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis prevention with sex hormone replacement therapy.
    Rozenberg S, Vandromme J, Kroll M, Pastijn A, Degueldre M.
    Int J Fertil Menopausal Stud; 1994 Oct 20; 39(5):262-71. PubMed ID: 7820159
    [Abstract] [Full Text] [Related]

  • 12. Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis.
    Levine JP.
    Curr Womens Health Rep; 2003 Jun 20; 3(3):181-6. PubMed ID: 12734027
    [Abstract] [Full Text] [Related]

  • 13. [Estrogens for treatment of osteoporoses].
    Higuchi T, Tarakida A, Abe K, Mizunuma H.
    Nihon Rinsho; 2009 May 20; 67(5):954-9. PubMed ID: 19432116
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
    Stevenson JC, International Consensus Group on HRT and Regulatory Issues.
    Hum Reprod; 2006 Jul 20; 21(7):1668-71. PubMed ID: 16556675
    [Abstract] [Full Text] [Related]

  • 17. [Bones are breaking without estrogen].
    Komulainen M, Tuppurainen M, Kröger H.
    Duodecim; 2003 Jul 20; 119(22):2183-9. PubMed ID: 14702807
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 20; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.